Article Text

PDF

FRI0052 To evaluate antibodies antinuclear (ana) in rheumatoid arthritis with infliximab treatmentoid
  1. F Gamero- Ruiz1,
  2. G Bonilla1,
  3. G Diaz1,
  4. JM Gonzalez-Tarrio2,
  5. R Alvarez-Doforno2,
  6. A Balsa1,
  7. E Martin-Mola1
  1. 1Rheumatology
  2. 2Inmunology Service, Hospital La Paz, Madrid, Spain

Abstract

Objectives To examine the evolution of the ANA titre in patients with rheumatoid arthritis treated with infliximab (anti TNF- alpha).

Methods 14 patients with active rheumatoid arthritis and unresponsive to at least 3 DMARDs were treated with methotrexate and infliximab. Before infliximab infusion, weeks 0, 2,6,14 and 22, a physical examination, DAS 28 and blood test, which included RF, ANA, immunoglobulin quantification C3 and C4 were done.

Results At the baseline visit 5/14 (35,71%) patients had positive ANA test,2 (1/40),1 (1/80),1 (1/160), 1 (1/640). After the fifth infusion 8/14 (57,14%) had a positive ANA test. Three patients who initially were ANA negative showed a titre of 1/160,1/320 and 1/640. Three out of 5 patients which previously had a positive test, showed an increase in the ANA titre,1/40 to 1/80,1/40 to 1/320 and 1/640 to 1/1280. After the fourth infusion of infliximab, all patients with ANA positive had a Crithidia test performed. In all cases anti DNA were negative.

Conclusion In our experience, treatment with infliximab has shown an increase of the ANA titre in 21,42% of the patients. On the other hand, 21,4% of the patients with a previous negative test for ANA had a positive test after the fourth infusion. All cases were negative for anti-DNA antibodies.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.